AGXT and glioma: Given the evidence suggesting that de novo biosynthesis can be targeted to disrupt the sphingolipid rheostat of certain IDHwt gliomas [74], this novel class of SPT inhibitors should be evaluated as potential therapeutic strategies against heterogeneous glioma lines [155,157,158].